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ment of patients with MPC as it delivers a survival advantage at a moderate price 
increase.
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Objectives: To estimate the threshold price (TP) of regorafenib in Spain to be an 
efficient option in the treatment of unresectable and/or metastatic gastrointesti-
nal stromal tumors (GIST) that have progressed on imatinib and sunitinib, com-
pared with the best supportive care (BSC). MethOds: The TP is the maximum 
price at which regorafenib offers an efficient incremental cost-utility ratio (ICUR) 
in Spain (≤ 30,000 € /QALY). A probabilistic cost-utility Markov model of GIST treat-
ment was developed initially in Excel to estimate costs and benefits of regorafenib 
compared with the BSC, from a National Health System perspective, in a lifetime 
horizon. Efficacy (overall survival and progression-free survival) and utilities were 
extracted from the GRID study, and cost values (drugs, visits, monitoring, adverse 
events, and end-of-life costs), from Spanish databases and published data. Then, 
the TP was estimated by using the Solver Add-in and a cost utility analysis was 
performed. Results: The initial model estimated a total cost of 33,256 € (95CI: 
27,909-38,324), and utility of 1.718 QALY (95CI: 1,506-1,757) with regorafenib; the 
estimated values of BSC were 6,546 € (95CI: 5,637-7,026) and 1.073 QALY (95CI: 0.902-
1.112), respectively.The TP of regorafenib was estimated in 2.234 € , and the total 
cost was 25,901 € (95CI: 21,912-29,409), showing a difference compared to BSC of 
19,356 € (95CI: 16,431-21,376); the ICUR was 30,000 € /QALY (95CI: 25,556-35,795). 
The probability of cost-effectiveness with regorafenib was 51.8%, for a willingness 
to pay of 30,000 € /QALY. cOnclusiOns: Below an ex-factory price of 2.234€ , the 
treatment with regorafenib in unresectable and/or metastatic GIST whose disease 
has progressed on imatinib and sunitinib represents a cost effectiveness assigna-
tion of resources.
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Objectives: Autologous peripheral stem cell transplantation (ASCT) with high-dose 
chemotherapy is a preferred treatment for non-Hodgkin’s lymphoma (NHL) patients. 
Granulocyte colony-stimulating factor (G-CSF) with plerixafor (G+P) is superior to 
G-CSF alone for stem cell mobilization (SCM) in heavily pretreated NHL patients. The 
main aim of this study was to perform comparative pharmacoeconomic analysis of 
using G+P versus G-CSF as a method for SCM. MethOds: Analysis of the published 
clinical trials was conducted to evaluate comparative efficacy and safety of the 
studied therapy options. Taking into account the hypothesis of superior effective-
ness of combination G+P for SCM for pharmacoeconomic analysis was chosen 
“cost-utility” analysis. For this study was adopted a Markov model simulated the 
care process of NHL patients undergoing ASCT using data from the Washington 
University site of the plerixafor Phase III study (Kymes SM. et al, 2012). Direct medical 
costs included diagnosis, mobilization and remobilization costs, aphaeresis, CD34+ 
cell processing and cryopreservation. Mobilization and remobilization costs were 
defined to be the costs of medical procedures, resource utilization, and medica-
tions. The incremental cost-utility ratio (ICUR) was estimated. One-way sensitiv-
ity analysis was made. Results: According to published trials the combination 
G+P has been shown to mobilize more CD34+ cells than G-CSF alone for ASCT. 
Additionally, G+P mobilization resulted in more predictable days of collection, no 
weekend aphaeresis procedures, and no unscheduled hospital admissions. The 
expected lifetime cost of providing care for NHL patients using G+P was 601 294 
rubles ($11 227) more than G-CSF, but they accumulated 1.75 more quality adjusted 
life years (QALYs) for an ICUR of 343 596 rubles ($6 415)/QALY. The one-way sensitiv-
ity analysis showed that the results are more sensitive to the variations of key model 
parameter, such as price of plerixafor. cOnclusiOns: Using G+P for SCM in ASCT of 
patients with NHL was more effective and economically justified treatment option.
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Objectives: Therapy of non-small cell lung cancer is a very complex clinical prob-
lem. Revealing of an optimum version of therapy requires not only the analysis 
of data by clinical efficiency, but also assessments of efficiency of expenses for 
applied medical products. Objective of research was an assessment the efficiency 
of expenses of Gefitinibum in patients with non-small cell lung cancer as a second 
line therapy. MethOds: Modelling was made on the basis of results of clinical 
researches INTEREST. We considered only direct medical costs. Expenses for cor-
rection of the side effects cased hospitalization were counted on tariffs Compulsory 
Medical Service in St. Petersburg, 2013. Costs of compared medicines (Docetaxelum, 
Pemetrexed) were received from results of auctions for 01.08.2012-01.06.2013 (a 
database “Cursor”). Results: Data of the research had shown that in case of an 
inefficiency of chemotherapy of the first line therapy, Gefitinibum increased life 
expectancy in view of it’s quality on 0,013 QALY and provide savings the 276 USD for 
1 patient in comparison with original Docetaxelum. Costs for 1 month without pro-
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Objectives: To assess the incremental cost‐effectiveness ratio (ICER) of obinutu-
zumab in association with chlorambucil (GClb) for CLL previously untreated patients 
unsuitable for full-dose fludarabine based therapy, in the Portuguese National 
Health Service (NHS) perspective. Comparators are rituximab in association with 
chlorambucil (RClb) and chlorambucil alone (Clb). MethOds: A Markov model 
developed by Roche was used to predict disease progression and mortality, assum-
ing weekly cycles and a 25 years’ time horizon. Pre‐progression clinical data was 
based on CLL11 clinical trial (Goede et al.; 2015), and post‐progression data based 
on Eichhorst et al. (2009). Utility values were obtained on Kosmas et al. (2014). Only 
direct medical costs were included, being resource consumption estimated through 
a seven Portuguese experts panel and unit costs taken from official sources. A 5% 
discount rate was applied to both costs and consequences. Results: In comparison 
to RClb, GClb use allows an increase of 0.69 life years (LY) and of 0.66 quality adjusted 
life years (QALY) that are associated to an additional cost of 12,472€ . When compared 
to Clb, the use of GClb increases clinical gains by 1.07 LY and 0.99 QALYs at an addi-
tional cost of 24,104€ . Consequently, GClb costs 18,112€ per LY and 18,948€ per QALY 
in comparison to RClb and 22,447€ per LY and 24,352€ per QALY in comparison to 
Clb. Sensitivity analysis shows that results are mainly sensitive to the extrapolation 
methods of pre‐progression survival and to utility values. cOnclusiOns: The use 
of obinutuzumab in association with chlorambucil for CLL previously untreated 
patients that are unsuitable for full-dose fludarabine based therapy implies added 
costs per LY and per QALY that are generally accepted in Portugal. The cost‐effec-
tiveness ratios of obinutuzumab in association with chlorambucil (GClb) are below 
25,000€ when compared both to rituximab in association with chlorambucil (RClb) 
and to chlorambucil alone (Clb).
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Objectives: This study aimed to assess the cost-effectiveness of first-line treat-
ment of patients with cetuximab in combination with either FOLFOX or FOLFIRI 
with wild type rat sarcoma viral oncogene (RASwt) metastatic colorectal cancer 
in Belgium (B) and the Netherlands (NL) compared with treatment with FOLFOX 
or FOLFIRI. MethOds: A Markov model was developed to estimate the incremen-
tal cost-utility ratios (ICURs) of the following first-line treatment comparisons: 
cetuximab + FOLFIRI vs. FOLFIRI and cetuximab + FOLFOX vs. FOLFOX. The model 
was populated with trial data where possible. Only head-to-head trials were con-
sidered including cetuximab and RASwt data. Survival was estimated based on a 
disease modelling approach. Two versions of the model were created; one for NL 
and one for B. Country specific costs were included and second- and third-line 
treatments differed between NL and B. In line with the country’s health economic 
guidelines, analyses were conducted from a societal perspective (NL) or a health care 
perspective (B). Costs were discounted with 4% (NL) or 3% (B) and effects with 1.5%. 
The models adopted a 20 year time-horizon. A probabilistic sensitivity analysis 
was conducted to account for uncertainty. Results: The ICURs for NL and B were 
€ 86,180 and € 55,430 for cetuximab + FOLFIRI vs. FOLFIRI and € 83,151 and € 42,453 
for cetuximab + FOLFOX vs. FOLFOX. Uncertainty around the ICURs was relatively 
small in the FOLFIRI arms and considerable in the FOLFOX arms. cOnclusiOns: 
NL and B have no official ICUR thresholds, but unofficial upper limits are assumed 
to be around € 80,000 in NL and € 45,000 in B. ICURs were close to these limits. ICURs 
differed strongly between NL and B. This was mainly caused by lower drug costs in B.
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Objectives: Nab-paclitaxel is a solvent-free paclitaxel formulation approved for 
first-line treatment of patients with metastatic pancreatic cancer (MPC) in combi-
nation with gemcitabine. Treatment with nab-paclitaxel and gemcitabine has been 
shown to be clinically effective in an area of high unmet need. Patients treated 
with nab-paclitaxel and gemcitabine had an increase in median survival of 3.3 
months compared to those treated with gemcitabine alone in patient subgroup 
with Karnofsky Performance Score 70-80. MethOds: A Markov cohort model was 
constructed for patients with MPC to examine the costs and outcomes of nab-
paclitaxel and gemcitabine versus gemcitabine. Health outcomes were expressed 
in terms of life-years (LYs) and quality-adjusted life-years (QALYs) gained. Patient’s 
disease progression over time was modeled using data from the MPACT study. An 
area under the curve methodology was used to characterize patients’ disease status 
at different points in time. Parametric curves were fitted to the overall survival data, 
progression-free survival data and time on treatment data. Health Related Quality 
of Life data for each health state was sourced systematically from the literature. 
Resource unit costs and use were derived from local cross-sectional survey. The 
analysis was performed from payer’s perspective in Slovak settings. Results: The 
base case result was an incremental cost-effectiveness ratio (ICER) of € 27,769 per 
QALY gained for paclitaxel albumin plus gemcitabine versus gemcitabine, based on 
an incremental cost of € 5,943, incremental survival of 3.3 months and incremental 
QALYs of 0.214. The key driver of the incremental costs was the additional drug 
acquisition cost of adding nab-paclitaxel to gemcitabine. cOnclusiOns: € 28 820 
per QALY is defined as the upper limit for conditional reimbursement in Slovakia. 
Nab-paclitaxel and gemcitabine is the cost-effective option for the first-line treat-
